Blackstone Life Sciences, Boston Scientific Agree to $455 Million Heart-Pump Development Collaboration
The collaboration will co-fund development of Boston Scientific’s VITALYST temporary circulatory support system for patients with cardiogenic shock.
Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE:BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart…